MARKET OUTLOOK
According to Triton, the hyperphosphatemia drugs market in Latin America is expected to proliferate with a CAGR of 17.20% in the forecast period of 2019-2027.
Brazil, Mexico and countries in rest of Latin America together constitute the hyperphosphatemia drugs market in the Latin American region.
Hyperphosphatemia is a condition that raises the phosphate levels in the blood. This condition can be caused because of the movement of phosphate from intracellular to extracellular space, unreasonable phosphate admission and diminishing in the discharge of phosphate. The elevated amounts of phosphate in the blood can be controlled by dietary limitations and with the utilization of phosphate binders. Hyperphosphatemia is an essential driver of bleakness and mortality in patients with persistent kidney illness. Hyperphosphatemia and expanded danger of death from cardiovascular sickness/vascular calcification are emphatically connected. This has expanded the danger of cardiovascular infection among the patients that have been reported to be suffering from hyperphosphatemia.
The rising prevalence of chronic diseases, increase in public awareness and the rise in the aging population are factors boosting the hyperphosphatemia drugs market. Furthermore, the growth of the market is propelled by the rising cases of osteoporosis and the changing dietary routine. However, non-adherence to treatment regiments, limited availability of drugs and use of advanced dialysis techniques are the key challenges faced by the market.
COMPETITIVE OUTLOOK
The prominent players in the market are Zeria Pharmaceutical, Johnson and Johnson, Keryx Biopharmaceuticals, Inc., Sun Pharmaceutical Industries, Ltd., Royal DSM N.V., Cipla, Fermenta Biotech, Ltd., Roche Diagnostics Corporation, Sanofi, Ultragenyx Pharmaceutical, Inc., Fresenius Medical Care, Shire, Pfizer, Inc., AMAG Pharmaceuticals, Bio-Tech Pharmacal and Bruno Farmaceutici S.p.A.